These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30878826)

  • 1. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
    Ma X; Wei J; Wang C; Gu D; Hu Y; Sheng R
    Eur J Med Chem; 2019 May; 170():112-125. PubMed ID: 30878826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
    Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
    Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
    Liu L; Shi B; Li X; Wang X; Lu X; Cai X; Huang A; Luo G; You Q; Xiang H
    Bioorg Med Chem; 2018 Aug; 26(15):4537-4543. PubMed ID: 30077608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models.
    Moreno O; Wood J
    Target Oncol; 2019 Oct; 14(5):603-611. PubMed ID: 31506873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.
    Gong YP; Tang LQ; Liu TS; Liu ZP
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structurally novel PI3Kδ/γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation.
    Tao Q; Chen Y; Liang X; Hu Y; Li J; Fang F; Wang H; Meng C; Liang J; Ma X; Gui S
    Eur J Med Chem; 2020 Apr; 191():112143. PubMed ID: 32078865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors.
    Xin M; Hei YY; Zhang H; Shen Y; Zhang SQ
    Bioorg Med Chem Lett; 2017 May; 27(9):1972-1977. PubMed ID: 28325601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia.
    Tang Y; Zheng Y; Hu X; Zhao H; Cui S
    J Med Chem; 2024 Apr; 67(8):6638-6657. PubMed ID: 38577724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):651-656. PubMed ID: 29536777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformationally restricted quinazolone derivatives as PI3Kδ-selective inhibitors: the design, synthesis and biological evaluation.
    Ma X; Fang F; Tao Q; Shen L; Zhong G; Qiao T; Lv X; Li J
    Medchemcomm; 2019 Mar; 10(3):413-420. PubMed ID: 30996859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.
    Feng Y; Duan W; Fan S; Zhang H; Zhang SQ; Xin M
    Bioorg Med Chem; 2019 Oct; 27(19):115035. PubMed ID: 31434616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
    Liu L; Li X; Cheng Y; Wang L; Yang H; Li J; He S; Shuangjie Wu ; Yin Q; Xiang H
    Eur J Med Chem; 2019 Feb; 164():304-316. PubMed ID: 30605829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and SAR study of potent and selective PI3Kδ inhibitors.
    Bui M; Hao X; Shin Y; Cardozo M; He X; Henne K; Suchomel J; McCarter J; McGee LR; San Miguel T; Medina JC; Mohn D; Tran T; Wannberg S; Wong J; Wong S; Zalameda L; Metz D; Cushing TD
    Bioorg Med Chem Lett; 2015 Mar; 25(5):1104-9. PubMed ID: 25666823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
    Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J
    Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
    Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
    Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3Kδ inhibitors.
    Wang NY; Zuo WQ; Hu R; Wang WL; Zhu YX; Xu Y; Yu LT; Liu ZH
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127479. PubMed ID: 32784091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas.
    Lou SY; Zheng FL; Tang YM; Zheng YN; Lu J; An H; Zhang EJ; Cui SL; Zhao HJ
    Life Sci; 2024 Jun; 347():122662. PubMed ID: 38670450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.